^
BIOMARKER:

ALK mutation

i
Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Entrez ID:
ALK mutation
NSCLC
pembrolizumab
Sensitive: A1 - Approval
ALK mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
ALK mutation
NSCLC
ceritinib
Sensitive: A2 - Guideline
ALK mutation
NSCLC
lorlatinib
Sensitive: A2 - Guideline
ALK mutation
NSCLC
sintilimab
Sensitive: C2 – Inclusion Criteria
ALK mutation
NSCLC
EGFR inhibitor
Sensitive: C3 – Early Trials
ALK mutation
NSCLC
ALK inhibitor
Sensitive: C3 – Early Trials
ALK mutation
NSCLC
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
ALK mutation
NSCLC
alectinib
Sensitive: C3 – Early Trials
ALK mutation
Melanoma
entrectinib
Resistant: C4 – Case Studies
ALK mutation
Melanoma
crizotinib
Sensitive: C4 – Case Studies